Mitiglinide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.^[1]

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells.

Dosage

Mitiglinide is delivered in tablet form.

References

↑ Malaisse WJ (October 2008). “Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients”. Expert Opin Pharmacother. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455.

External links

Elixir Pharmaceuticals – website of the U.S. rights holder for mitiglinide.

Template:Oral hypoglycemics

[pmid18803455-1] Malaisse WJ (October 2008). “Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients”. Expert Opin Pharmacother. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455.

[1]